Table 3 Specific clinical issues and patient medical conditions sorted by descending order based on all participants’ mean importance score (0 = “Not At All Important,” 10 = “Extremely Important”)
Clinical Issue/Patient Medical Condition | All Participants | Anesthesia Care Providers | Surgeons |
|---|---|---|---|
(N = 83) | (N = 48) | (N = 35) | |
Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | |
Coronary artery stents | 9.2 (9.0, 9.4) | 9.2 (9.0, 9.5) | 9.2 (8.9, 9.6) |
Airway management | 9.1 (8.8, 9.5) | 8.9 (8.4, 9.5) | 9.4 (9.0, 9.8) |
Myocardial infarction or injury after non-cardiac surgery | 9.1 (8.8, 9.4) | 9.2 (8.9, 9.5) | 8.9 (8.4, 9.4) |
Malignant hyperthermia | 9.1 (8.7, 9.5) | 9.2 (8.7, 9.7) | 8.8 (8.1, 9.5) |
Ventilation | 9.1 (8.8, 9.4) | 9.0 (8.5, 9.5) | 9.2 (8.8, 9.6) |
Implantable cardioverter defibrillators | 8.9 (8.7, 9.2) | 9.0 (8.7, 9.3) | 8.8 (8.4, 9.2) |
Pulmonary hypertension | 8.9 (8.6, 9.2) | 9.1 (8.8, 9.4) | 8.5 (8.0, 9.0) |
Congestive heart failure | 8.8 (8.6, 9.1) | 9.0 (8.6, 9.3) | 8.6 (8.2, 9.0) |
Cardiomyopathy | 8.8 (8.5, 9.1) | 8.9 (8.6, 9.3) | 8.6 (8.2, 9.1) |
Coronary artery disease | 8.7 (8.5, 9.0) | 8.8 (8.5, 9.2) | 8.6 (8.1, 9.0) |
Anticoagulants | 8.7 (8.3, 9.1) | 8.3 (7.8, 8.8) | 9.3 (8.9, 9.7) |
Cardiac arrhythmias | 8.6 (8.4, 8.9) | 8.7 (8.3, 9.0) | 8.6 (8.2, 9.0) |
Preoperative antimicrobial prophylaxis and skin preparation | 8.6 (8.2, 9.0) | 8.4 (7.8, 9.0) | 9.0 (8.6, 9.4) |
Cardiac pacemakers | 8.6 (8.3, 8.9) | 8.6 (8.2, 9.0) | 8.6 (8.1, 9.1) |
Acute kidney injury and renal failure | 8.5 (8.2, 8.9) | 8.8 (8.4, 9.2) | 8.2 (7.6, 8.8) |
Infection and sepsis | 8.5 (8.2, 8.8) | 8.4 (8.0, 8.8) | 8.7 (8.2, 9.1) |
Intraoperative hypothermia prevention (maintaining normothermia) | 8.4 (8.1, 8.8) | 8.6 (8.2, 9.0) | 8.2 (7.5, 8.9) |
Cardiovascular testing | 8.3 (8.0, 8.6) | 8.5 (8.1, 8.9) | 8.0 (7.4, 8.5) |
Cerebrovascular accident | 8.2 (7.9, 8.6) | 8.5 (8.1, 8.9) | 7.8 (7.1, 8.5) |
Patient medication instruction and compliance | 8.2 (7.9, 8.5) | 8.2 (7.8, 8.6) | 8.1 (7.6, 8.7) |
Laboratory testing | 8.2 (7.8, 8.5) | 8.3 (7.9, 8.7) | 8.0 (7.4, 8.5) |
Deep venous thrombosis | 8.1 (7.8, 8.5) | 7.9 (7.4, 8.5) | 8.4 (8.0, 8.9) |
Cerebrovascular disease | 8.1 (7.8, 8.4) | 8.4 (8.0, 8.7) | 7.8 (7.2, 8.3) |
Geriatric anesthetic and analgesic management | 8.1 (7.8, 8.4) | 8.2 (7.7, 8.7) | 7.9 (7.5, 8.4) |
Patient-centered blood management | 8.0 (7.7, 8.4) | 8.3 (7.8, 8.7) | 7.7 (7.2, 8.2) |
Trauma | 8 .0 (7.6, 8.5) | 8.5 (7.9, 9.0) | 7.3 (6.6, 8.1) |
Arterial hypertension | 8.0 (7.7, 8.3) | 8.1 (7.6, 8.6) | 7.9 (7.4, 8.3) |
Cirrhosis and liver failure | 8.0 (7.6, 8.4) | 7.9 (7.4, 8.3) | 8.2 (7.6, 8.8) |
Perioperative opioid sparing strategies (“multimodal analgesia”) | 7.9 (7.5, 8.3) | 8.2 (7.6, 8.7) | 7.5 (7.0, 8.0) |
Fluid and electrolyte management | 7.8 (7.4, 8.2) | 7.7 (7.1, 8.2) | 8.0 (7.5, 8.5) |
Beta-blockers | 7.8 (7.4, 8.2) | 7.6 (7.1, 8.1) | 8.0 (7.4, 8.6) |
Insulin pumps | 7.8 (7.4, 8.2) | 7.9 (7.4, 8.4) | 7.6 (6.8, 8.4) |
Obstructive sleep apnea | 7.8 (7.4, 8.1) | 7.8 (7.3, 8.3) | 7.7 (7.3, 8.2) |
Diabetes mellitus | 7.7 (7.4, 8.1) | 7.9 (7.4, 8.4) | 7.5 (6.9, 8.1) |
Chronic obstructive pulmonary disease | 7.7 (7.4, 8.1) | 7.7 (7.3, 8.1) | 7.9 (7.3, 8.4) |
Renal insufficiency | 7.5 (7.1, 7.9) | 7.4 (6.9, 8.0) | 7.6 (6.9, 8.3) |
Glucose management (not just in diabetics) | 7.5 (7.1, 7.8) | 7.5 (7.0, 8.0) | 7.5 (6.9, 8.0) |
Nausea and vomiting | 7.4 (7.0, 7.8) | 7.8 (7.3, 8.4) | 6.8 (6.2, 7.4) |
Choice of anesthetic technique and agents | 7.4 (6.9, 7.9) | 7.3 (6.6, 8.0) | 7.5 (6.8, 8.3) |
Preoperative physical conditioning (“prehabilitation”) | 7.4 (7.0, 7.8) | 7.6 (7.2, 8.1) | 7.0 (6.3, 7.7) |
Cognitive delirium | 7.3 (6.8, 7.8) | 7.6 (7.1, 8.2) | 6.8 (6.1, 7.5) |
Anemia | 7.3 (6.9, 7.7) | 7.3 (6.7, 7.8) | 7.3 (6.8, 7.8) |
Cognitive dysfunction | 7.3 (6.8, 7.7) | 7.6 (7.0, 8.2) | 6.7 (6.1, 7.3) |
Perioperative sedative sparing strategies | 7.2 (6.7, 7.7) | 7.5 (6.9, 8.1) | 6.7 (6.1, 7.4) |
Smoking cessation | 7.0 (6.5, 7.5) | 6.8 (6.1, 7.5) | 7.2 (6.5, 7.9) |
Chronic pain/chronic opioid use | 6.9 (6.5, 7.3) | 7.2 (6.6, 7.7) | 6.6 (6.1, 7.1) |
Substance abuse | 6.9 (6.6, 7.3) | 6.9 (6.4, 7.3) | 7.0 (6.4, 7.7) |
Obesity | 6.9 (6.4, 7.3) | 6.7 (6.1, 7.4) | 7.1 (6.5, 7.7) |
Other implantable devices (vagal nerve stimulators, deep brain stimulators) | 6.9 (6.4, 7.3) | 7.0 (6.3, 7.7) | 6.7 (6.0, 7.4) |
Nutrition | 6.8 (6.4, 7.2) | 6.4 (5.9, 7.0) | 7.4 (6.9, 7.9) |
Angiotensin receptor blockers | 6.8 (6.4, 7.2) | 7.2 (6.7, 7.7) | 6.2 (5.6, 6.8) |
Angiotensin-converting enzyme inhibitors | 6.8 (6.4, 7.1) | 7.1 (6.6, 7.6) | 6.2 (5.6, 6.8) |
Reported penicillin allergy | 6.7 (6.2, 7.2) | 6.9 (6.2, 7.5) | 6.4 (5.6, 7.2) |
Intrathecal pumps | 6.7 (6.2, 7.2) | 6.8 (6.2, 7.4) | 6.6 (5.7, 7.4) |
Calcium channel blockers | 6.5 (6.2, 6.9) | 6.5 (6.0, 7.1) | 6.6 (6.0, 7.2) |
Pulmonary function testing | 6.0 (5.4, 6.6) | 5.4 (4.6, 6.3) | 6.8 (6.1, 7.4) |
Diuretics | 5.8 (5.4, 6.3) | 5.6 (5.0, 6.2) | 6.1 (5.4, 6.8) |